Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

Medtronic, a leader in medical technology and Philips, a leader in health technology announced the signing of a Memorandum of ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

The Health Insurance Corp. (PhilHealth) has increased its coverage for open heart surgeries to almost P1 million and launched ...

Serious heart problems kept one local senior from dancing with his wife. But thanks to a life-saving procedure at White ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Discover how recent advancements in cardiovascular medicine, including TAVI and TEER, are revolutionizing heart disease ...

Sue Dumbauld got an alert from her Apple Watch that her heart rate was dangerously high. This inspired her to exercise ahead ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...